Kevin Hall

Kevin completed his D.Phil in the Inorganic Chemistry Laboratory at Oxford University on the ‘Chemistry of Gold Clusters’ subsequently joining 3M working in the field of imaging products such as medical X-ray film.

After a short period in inkjet technology he then transitioned to the DNA sequencing start-up Solexa Ltd. This company was acquired by Illumina Inc. in 2006 where he has worked since on the development of products dedicated to the sequencing of genomes. He created a group called Systems Integration that worked on the integration and testing of the software/hardware and assay platforms contributing to the successful launch of many of Illumina’s sequencing instruments.

More recently he has taken a global role working with key opinion leaders/medical researchers/government and non-government bodies to further the application of genomics and ‘unlocking the power of the genome’.

Based in Cambridge UK his interests in collaborations include rapid genomic sequencing of new born babies in critical care to establish disease causes (Stephen Kingsmore, Rady Children’s Hospital), population scale genomic sequencing (Singapore PRECISE 100k), new born screening and other frontier areas such as ancient and ocean DNA sequencing.